Core Points - Shanghai Yizhong Pharmaceutical Co., Ltd. reported on the status of its fundraising and actual usage for the first half of 2025, detailing the total amount raised and how it has been allocated [1][2][4] - The company raised a total of RMB 936.03 million, with a net amount of RMB 936.03 million after deducting issuance costs [1][2] - As of June 30, 2025, the remaining balance of the raised funds was RMB 424.52 million [1][2] Fundraising Overview - The company issued 26.45 million shares at a price of RMB 38.1 per share, resulting in total fundraising of RMB 1,007.75 million [1] - After deducting issuance costs of RMB 71.71 million, the net proceeds amounted to RMB 936.03 million [1] - The funds were deposited in designated accounts and managed according to regulatory requirements [1][2] Fund Management - The company established a fundraising management system to ensure the funds are used in a standardized, safe, efficient, and transparent manner [1][2] - Multiple bank accounts were opened for fund management, including accounts at Agricultural Bank of China, Bank of Communications, and China Merchants Bank [1][2] - The company has approved the temporary use of idle funds for cash management, with limits set for various periods [2][5] Actual Fund Usage - As of June 30, 2025, the company had invested RMB 580.45 million into projects, with RMB 70.77 million invested in the current period [1][4] - The company used RMB 142,358.49 for replacing self-raised funds that were used for issuance costs [1][5] - There were no instances of using excess funds for permanent working capital or repaying bank loans [2][5] Project Progress and Adjustments - The company reported delays in project timelines due to regulatory approvals and external environmental changes [4][6] - Adjustments were made to the investment amounts among different project entities to improve efficiency and ensure timely project completion [6] - The company is actively working on expanding its production capacity for the injectable paclitaxel polymer micelles [6]

Core Viewpoint - The company is committed to enhancing operational quality and core competitiveness while protecting the legitimate rights and interests of all investors, particularly small and medium-sized investors, through its "Quality Improvement, Efficiency Enhancement, and Return Focus" action plan for 2025 [1] Group 1: Business Development - The company focuses on the development of innovative anti-tumor drugs and related products, supported by a team of high-tech talents with backgrounds in polymer materials, drug formulation, and biology [1] - The company has achieved significant improvements in operational quality and efficiency, with core product marketing maintaining a steady performance [2] - The company has completed approvals for its products in over 200 key hospitals nationwide, enhancing drug accessibility and patient affordability [2] Group 2: Production Expansion - The company is implementing a project to produce 5 million injections of paclitaxel polymer micelles annually, with construction progressing smoothly and on schedule [3] - The cleanroom construction and production equipment preparations are underway, ensuring alignment with future market demand [3][4] Group 3: Clinical Research - The company is actively conducting clinical research for multiple cancer indications, with Phase II trials for ovarian, esophageal, and nasopharyngeal cancers progressing as planned [5] - Phase III trials for breast and pancreatic cancers have been initiated at over 20 research centers nationwide, with research progress meeting expectations [5] Group 4: Talent Acquisition - The company has successfully recruited 252 individuals in the first half of 2025, including 23 high-educated talents and 99 fresh graduates, enhancing its research and professional capabilities [6] Group 5: Innovation and R&D - The company is developing two new drugs: a multifunctional monoclonal antibody and a fourth-generation EGFR-TKI, both currently in preclinical research [6] - The focus for the year will be on advancing these new drugs through critical experiments to validate their efficacy and safety [6] Group 6: Investor Returns - The company emphasizes sustainable profitability and has implemented a cash dividend policy, distributing 0.3 yuan per share, totaling 43,166,400 yuan, which is 30.22% of the net profit attributable to shareholders [7][8] - The company has repurchased 1,274,307 shares, amounting to 37,240,964.92 yuan, reinforcing its commitment to maintaining long-term investment value [8] Group 7: Investor Communication - The company has enhanced its investor communication by expanding channels and improving the quality of information disclosure, thereby increasing investor confidence [9] - Regular training for key personnel has been conducted to ensure accurate and timely information disclosure, reflecting the company's investment value [9] Group 8: Corporate Governance - The company is continuously improving its governance structure and internal control systems to ensure stable operations and enhance financial management [10] - The company has revised key governance documents to clarify the responsibilities of its management team, aligning their performance with shareholder interests [10] Group 9: Future Outlook - The company will continue to focus on its main business development and maintain a stable and resilient long-term profitability, ensuring the protection of all shareholders' rights [11]

Core Viewpoint - Shanghai Yizhong (SH 688091, closing price: 76.37 yuan) announced on August 7 that its 11th meeting of the second board of directors was held, where the implementation assessment report of the "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan for 2025 was reviewed [2]. Financial Performance - For the year 2024, Shanghai Yizhong's revenue composition was as follows: chemical pharmaceuticals accounted for 99.71%, while other businesses made up 0.29% [2].

Core Insights - Shanghai Yizhong (SH 688091) reported a revenue of approximately 160 million yuan for the first half of 2025, representing a year-on-year increase of 31.48% [2] - The net profit attributable to shareholders was around 38 million yuan, reflecting a year-on-year growth of 10.13% [2] - Basic earnings per share reached 0.18 yuan, which is a year-on-year increase of 5.88% [2]

上海谊众致力于抗肿瘤创新药及相关产品的开发，拥有高分子材料、药物制剂、 生物学等背景的高科技人才，具备独立自主的药品研发能力与完整的药品生产系 统，是一家集研发、生产、销售为一体的高科技制药企业。 2025 年上半年，公司严格贯彻"提质增效重回报"行动方案，持续强化风险 管控，筑牢"安全、稳健"发展根基，为高效率、高质量的综合发展提供了坚实保 障。凭借在研发、生产、营销及产品价值创造等领域的核心竞争优势，公司坚定聚 焦主业发展，核心产品营销保持稳健态势。同时，公司高效推进募投项目建设与创 新药研发等关键经营工作，在重点领域取得显著提质增效成果，整体经营质量与效 率获得实质性提升，高质量发展迈出坚实步伐。 （一） 传递产品价值，夯实市场竞争基础 上海谊众药业股份有限公司关于 2025 年度"提质增效重回报"行动方案的 半年度评估报告 为深入贯彻"以投资者为本"的核心理念，持续提升经营发展质量与核心竞争 力，切实维护投资价值并保护全体投资者（特别是中小投资者）的合法权益，上海 谊众药业股份有限公司（以下简称"公司"）于 2025 年 6 月 7 日披露了《2025 年 度"提质增效重回报"行动方案》（以下简称"方 ...

上海谊众药业股份有限公司 募集资金存放与实际使用情况专项报告 上海谊众药业股份有限公司 2025 年半年度 募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司募集资金监管规则》和上海证券交易所《上海证券交易所科创板 上市公司自律监管指引第 1 号——规范运作》的规定，上海谊众药业股份有限公司 （以下简称本公司或公司）对 2025 年 1-6 月募集资金存放与使用情况报告如下： 一、募集资金基本情况 经中国证券监督管理委员会证监发行字[2021]2595 号文核准，本公司向社会公开 发行人民币普通股（A 股）2,645 万股，每股发行价为 38.1 元，应募集资金总额为人民 币 100,774.50 万元，根据有关规定扣除发行费用 7,171.45 万元后，实际募集资金净额 为 93,603.05 万元。该募集资金已于 2021 年 9 月 3 日到账，到账情况业经容诚会计师 事务所容诚验字【2021】201Z0041 号《验资报告》验证。 公司对募集资金采取了专户存储管理。 ...

证券代码：688091 证券简称：上海谊众 公告编号：2025-031 上海谊众药业股份有限公司及全资子公司使用部分 闲置募集资金进行现金管理的公告 注 1："年产 500 万支注射用紫杉醇聚合物胶束及配套设施建设"将由全资子公司上海联峥生物 科技有限公司投入 136,895,000.00 元用于生产综合厂房建设等土建工程，其余资金由上海谊众 负责自动化生产、检测及包装生产线建设，同时对现有能源供应、环保设施等进行改造建设等。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海谊众药业股份有限公司（以下简称"公司"或"上海谊众"）于 2025 年 8 月 7 日召开了第二届董事会第十一次会议，审议通过了《关于公司及全资子公司使用 部分闲置募集资金进行现金管理的议案》。同意公司及全资子公司在确保不影响募 集资金投资项目进度、不影响公司正常生产经营及确保资金安全的前提下，使用 额度不超过人民币 450,000,000.00 元的部分暂时闲置募集资金进行现金管理，用于 购买安全性高、流动性好、满足保本要求的产品（包括但不限于购 ...

证券代码：688091 证券简称：上海谊众 公告编号：2025-030 上海谊众药业股份有限公司 第二届董事会第十一次会议决议公告 2、审议通过《关于公司及全资子公司使用部分闲置募集资金进行现金管理的 议案》 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 上海谊众药业股份有限公司（以下简称"公司"）第二届董事会第十一次会议（以 下简称"会议"）于 2025 年 8 月 7 日以现场结合通讯方式召开，会议通知已于 2025 年 8 月 2 日以通讯方式送达全体董事。会议应出席董事 6 人，实际出席董事 6 人， 本次会议由公司董事长周劲松召集和主持。会议的召集和召开程序符合有关法律 法规的规定，会议决议合法、有效。 二、董事会会议审议情况 本次会议经全体董事表决，形成决议如下： 1、审议通过《关于上海谊众药业股份有限公司 2025 年半年度报告及报告摘要 的议案》 董事会认为：公司 2025 年半年度报告的编制和审议程序符合相关法律法规及 《公司章程》等内部规章制度的规定；公司 2025 年半年度报 ...

上海谊众药业股份有限公司2025 年半年度报告 公司代码：688091 公司简称：上海谊众 上海谊众药业股份有限公司 2025 年半年度报告 1 / 153 上海谊众药业股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 报告期内，公司不存在对生产经营构成实质性影响的重大风险。公司已在本报告中详述公司 在经营过程中可能面临的相关风险，详见本报告第三节"管理层讨论与分析"中"风险因素"的 相关内容。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人周劲松、主管会计工作负责人汤节节及会计机构负责人（会计主管人员）阮天 一声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 报告期内，公司无利润分配或资本公积金转增股本的预案。 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的关于公司未 ...

报告期内公司营业收入较上年同期增长31.48%，主要原因为核心产品紫杉醇胶束纳入国家医保目录， 销量较上年同期显著增长487%。 智通财经APP讯，上海谊众(688091.SH)披露2025年半年度报告，报告期实现营收1.6亿元，同比增长 31.48%;归母净利润3800万元，同比增长10.13%;扣非净利润3706万元，同比增长11.74%;基本每股收益 0.18元。 ...